The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects |
|---|---|
| Study Drug | VX19-445-115 |
| Type of Study Drug | CFTR modulation |
| Study Title | A Phase 3b, Open-label Study Evaluating the Safety of Elexacaftor Combination Therapy in Cystic Fibrosis Subjects, Homozygous for F508del |
| Study Phase | 3B |
| Study Sponsor | Vertex |
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=VX19-445-115 |
|
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | CF subjects who are 12 years of age or older |